Longitudinal monitoring of circulating tumor DNA to detect relapse early and predict outcome in early breast cancer
Breast Cancer Research and Treatment · 2025-02 · 209 (3) · 493-502
DOI: 10.1007/s10549-024-07508-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Breast Cancer Research and Treatment, online erschienen am 18.10.2024. Verfasst von Isaac Garcia-Murillas und 22 weiteren Autor:innen. Beteiligte Einrichtung: The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK. Hauptthemen laut MEDLINE: Circulating Tumor DNA, Breast Neoplasms, Neoplasm Recurrence, Local, Biomarkers, Tumor. Die Arbeit wurde bisher 53-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Breast Cancer Now Toby Robins Research Centre Grant Number, Invitae Corp, Le Cure and RM Charity.
Abstract (Originalsprache)
PURPOSE: Detection of molecular residual disease (MRD) allows for the identification of breast cancer patients at high-risk of recurrence, with the potential that early initiation of treatment at early stages of relapse could improve patient outcomes. The Invitae Personalized Cancer Monitoring™ assay (PCM) is a newly developed next-generation sequencing approach that utilizes up to 50 patient-specific, tumor-informed DNA variants, to detect circulating tumor DNA (ctDNA). The ability of the PCM assay to detect MRD before clinical relapse was evaluated. METHODS: The cohort included 61 female patients with high-risk breast cancer who underwent neoadjuvant chemotherapy. Plasma samples were collected before and during neoadjuvant therapy, after surgery and during monitoring. PCM was used to detect ctDNA at each time point. RESULTS: The sensitivity to detect ctDNA in plasma from patients who relapsed during the monitoring phase was 76.9% (10/13). Specificity and positive predictive values were both 100% with all (10/61, 16%) of the patients who had ctDNA detected during the monitoring phase subsequently relapsing. Detection of ctDNA during monitoring was associated with a high-risk of future relapse (HR 37.2, 95% CI 10.5-131.9, p < 0.0001), with a median lead-time from ctDNA detection to clinical relapse of 11.7 months. CONCLUSION: PCM detected ctDNA in patients who relapsed with a long lead-time over clinical relapse, shows strong association with relapse-free survival and may be used to identify patients at high-risk for relapse, allowing for earlier intervention.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.
- Breast Unit, Royal Marsden Hospital, London, UK.
- Labcorp Genetics, Inc, San Francisco, CA, USA.
- Former Employees of Invitae Corp, San Francisco, CA, USA.
- Hinchingbrooke Hospital, Hinchingbrooke Park, Huntingdon, UK.
- Poole General Hospital, Dorset, UK.
Förderung
- Breast Cancer Now Toby Robins Research Centre Grant Number
- Invitae Corp
- Le Cure and RM Charity
- NIHR
Zitieren
APA
Garcia-Murillas, I., Cutts, R. J., Walsh-Crestani, G., Phillips, E., Hrebien, S., Dunne, K., Sidhu, K., Daber, R., Hubert, B., Graybill, C., DeFord, P. M., Wooten, D. J., Zhao, J., Ellsworth, R. E., Johnston, S. R. D., Ring, A., Russell, S., Evans, A., Skene, A., …, & Turner, N. C. (2025). Longitudinal monitoring of circulating tumor DNA to detect relapse early and predict outcome in early breast cancer. Breast Cancer Research and Treatment, 209(3), 493-502. https://doi.org/10.1007/s10549-024-07508-2
Vancouver
Garcia-Murillas I, Cutts RJ, Walsh-Crestani G, Phillips E, Hrebien S, Dunne K, et al. Longitudinal monitoring of circulating tumor DNA to detect relapse early and predict outcome in early breast cancer. Breast Cancer Research and Treatment. 2025;209(3):493-502. doi:10.1007/s10549-024-07508-2
BibTeX
@article{GarciaMurillas2025,
author = {Garcia-Murillas, Isaac and Cutts, Rosalind J and Walsh-Crestani, Giselle and Phillips, Edward and Hrebien, Sarah and Dunne, Kathryn and Sidhu, Kally and Daber, Robert and Hubert, Benjamin and Graybill, Chiharu and DeFord, Peter M and Wooten, David J and Zhao, Jianhua and Ellsworth, Rachel E and Johnston, Stephen R D and Ring, Alistair and Russell, Simon and Evans, Abigail and Skene, Anthony and Wheatley, Duncan and Smith, Ian E and Korn, W Michael and Turner, Nicholas C},
title = {Longitudinal monitoring of circulating tumor DNA to detect relapse early and predict outcome in early breast cancer},
journal = {Breast Cancer Research and Treatment},
year = {2025},
volume = {209},
number = {3},
pages = {493--502},
doi = {10.1007/s10549-024-07508-2}
}
EUVIMED